Suppr超能文献

莫尔基奥B病患者中突变型β-半乳糖苷酶的底物特异性失衡。

Imbalanced substrate specificity of mutant beta-galactosidase in patients with Morquio B disease.

作者信息

Okumiya Toshika, Sakuraba Hitoshi, Kase Ryoichi, Sugiura Tetsuro

机构信息

Department of Laboratory Medicine, Faculty of Medicine, Kochi Medical School, Oko-cho, Nankoku, Kochi 783-8505, Japan.

出版信息

Mol Genet Metab. 2003 Jan;78(1):51-8. doi: 10.1016/s1096-7192(02)00199-3.

Abstract

G(M1)-gangliosidosis and Morquio B disease are distinct in clinical and biochemical features, but both disorders are caused by genetic defects of the same enzyme, acid beta-galactosidase (beta-Gal). We analyzed the kinetic properties of mutant beta-Gals from patients with G(M1)-gangliosidosis and Morquio B disease to examine the clinical and biochemical differences between both disorders. Five skin fibroblast lines from patients with G(M1)-gangliosidosis (2 cases; R201C/R201C and I51T/I51T), Morquio B disease (2 cases; W273L/W273L and Y83H/R482C), and galactosialidosis (1 case; Y395C/S90L) were used as enzyme sources. Residual enzyme activity in the cells was subjected to kinetic analysis. Substrate analogs including Galbeta1-3GalNAc, as an analog for G(M1)-ganglioside, and Galbeta1-4GlcNAc, as an analog for keratan sulfate, were used to determine IC(50) and K(i) for beta-Gals with an artificial substrate (4-methylumbelliferyl beta-D-galactopyranoside). Enzymatic assay method was established to examine the hydrolytic activity with the mutant beta-Gal for the substrate analogs. The mutant beta-Gal activities were inhibited by Galbeta1-3GalNAc and Galbeta1-4GlcNAc in a concentration-dependent manner. Remarkable increase in IC(50) ratio and K(i) ratio (Galbeta1-4GlcNAc/Galbeta1-3GalNAc) was observed in Morquio B disease. Relative hydrolytic activity (Galbeta1-4GlcNAc/Galbeta1-3GalNAc) was markedly decreased in Morquio B disease as compared with other subjects; controls (means+/-SD, n=4), 1.00+/-0.02; galactosialidosis, 1.03; G(M1)-gangliosidosis, 1.15 and 1.00; and Morquio B disease, 0.27 and 0.32. The mutant beta-Gals from the patients with Morquio B disease exhibited lower affinity and lower hydrolytic activity toward Galbeta1-4GlcNAc rather than Galbeta1-3GalNAc. These findings suggest that imbalanced substrate specificity of the mutant beta-Gals induces predominant accumulation of keratan sulfate and a rationale for performing differential diagnostic analysis for both disorders.

摘要

GM1神经节苷脂贮积症和莫尔基奥B病在临床和生化特征上有所不同,但这两种疾病均由同一种酶——酸性β-半乳糖苷酶(β-Gal)的基因缺陷引起。我们分析了GM1神经节苷脂贮积症和莫尔基奥B病患者的突变β-Gal的动力学特性,以研究这两种疾病在临床和生化方面的差异。使用了来自GM1神经节苷脂贮积症患者(2例;R201C/R201C和I51T/I51T)、莫尔基奥B病患者(2例;W273L/W273L和Y83H/R482C)以及半乳糖唾液酸贮积症患者(1例;Y395C/S90L)的5条皮肤成纤维细胞系作为酶源。对细胞中的残余酶活性进行动力学分析。使用包括Galβ1-3GalNAc(作为GM1神经节苷脂的类似物)和Galβ1-4GlcNAc(作为硫酸角质素的类似物)在内的底物类似物,以人工底物(4-甲基伞形酮基β-D-吡喃半乳糖苷)测定β-Gal的IC50和Ki。建立了酶活性测定方法以检测突变β-Gal对底物类似物的水解活性。突变β-Gal的活性受到Galβ1-3GalNAc和Galβ1-4GlcNAc的浓度依赖性抑制。在莫尔基奥B病中观察到IC50比值和Ki比值(Galβ1-4GlcNAc/Galβ1-3GalNAc)显著增加。与其他受试者相比,莫尔基奥B病中的相对水解活性(Galβ1-4GlcNAc/Galβ1-3GalNAc)显著降低;对照组(均值±标准差,n = 4),1.00±0.02;半乳糖唾液酸贮积症,1.03;GM1神经节苷脂贮积症,1.15和1.00;莫尔基奥B病,0.27和0.32。来自莫尔基奥B病患者的突变β-Gal对Galβ1-4GlcNAc的亲和力和水解活性低于对Galβ1-3GalNAc的亲和力和水解活性。这些发现表明,突变β-Gal的底物特异性失衡导致硫酸角质素的主要蓄积,这为对这两种疾病进行鉴别诊断分析提供了理论依据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验